Central venous access device (CVAD) complications in Haemophilia with inhibitors undergoing immune tolerance induction: Lessons from the international immune tolerance study

Haemophilia

Volumn 21, Issue 5, 2015, Pages e369-e374

  Rodriguez, V ^a   Mancuso, M E ^b   Warad, D ^a   Hay, C R M ^c   Dimichele, D M ^d,i   Valentino, L ^e,j   Kenet, G ^f,g   Kulkarni, R ^h  

^a MAYO CLINIC   (United States)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e RUSH UNIVERSITY MEDICAL CENTER   (United States)

^f SHEBA MEDICAL CENTER   (Israel)

^g TEL AVIV UNIVERSITY   (Israel)

^h MICHIGAN STATE UNIVERSITY   (United States)

ⁱ NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^j BAXTER HEALTHCARE CORPORATION   (United States)

more..

Author keywords

Central venous access; Complications; Immune tolerance; Inhibitors

Indexed keywords

BLOOD CLOTTING FACTOR 8 INHIBITOR; ANTIBODY;

ARTICLE; CATHETER INFECTION; CHILD; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HEMOPHILIA; HIGH RISK PATIENT; HUMAN; IMMUNOLOGICAL TOLERANCE; INFANT; INFECTION RATE; INFECTION RISK; INTRAVENOUS CATHETER; MAJOR CLINICAL STUDY; NEWBORN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; TREATMENT OUTCOME; TREATMENT PLANNING; ADVERSE EFFECTS; CENTRAL VENOUS CATHETERIZATION; HEMOPHILIA A; IMMUNOLOGY; INTERNATIONAL COOPERATION; PRESCHOOL CHILD; PROSTHESIS-RELATED INFECTIONS; RISK FACTOR; TIME FACTOR;

ANTIBODIES; CATHETERIZATION, CENTRAL VENOUS; CHILD; CHILD, PRESCHOOL; HEMOPHILIA A; HUMANS; IMMUNE TOLERANCE; INFANT; INFANT, NEWBORN; INTERNATIONALITY; PROSTHESIS-RELATED INFECTIONS; RISK FACTORS; TIME FACTORS;

EID: 84942125415     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12740     Document Type: Article

References (32)

1. Mannucci PM, Tuddenham EDG. The hemophiliac - From royal genes to gene therapy. N Engl J Med 2001; 344: 1773-9.
2. Berntorp E, Astermark J, Bjorkman S et al. Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia 2003; 9(Suppl. 1): 1-4.
3. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
4. Iorio A, Halimeh S, Holzhauer S et al. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. J Thromb Haemost 2010; 8: 1256-65.
5. Ehrenforth S, Kreuz W, Linde R et al. Incidence of development of factor VIII and factor IX inhibitors in haemophilias. Lancet 1992; 339: 594-8.
6. Sultan Y, the French Hemophilia Study Group. Prevalence of inhibitors in a population of 3435 hemophilia patients in France. Thromb Haemost 1992; 67: 600-2.
7. Katz J. Prevalence of factor IX inhibitors among patients with haemophilia B: results of a large-scale North American survey. Haemophilia 1996; 2: 28-31.
8. DiMichele DM. Inhibitors: resolving diagnostic and therapeutic dilemmas. Haemophilia 2002; 8: 280-3.
9. DiMichele DM, Hoots WK, Pipe SW, Rivard GE, Santagostino E. International workshop on immune tolerance induction: consensus recommendations. Haemophilia 2007; 13(Suppl. 1): 1-22.
10. Brackmann HH, Gormsen J. Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder. Lancet 1977; 2: 933.
11. Oldenburg J, Schwaab R, Brackmann HH. Induction of immune tolerance in HA inhibitor patients by the 'Bonn Protocol': predictive parameter for therapy duration and outcome. Vox Sang 1999; 77: 49-54.
12. Kroner BL. Comparison of the international immune tolerance registry and the North American immune tolerance registry. Vox Sang 1999; 77(Suppl. 1): 33-7.
13. DiMichele DM, Kroner BL. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost 2002; 87: 52-7.
14. Lenk H. The German registry of ITT in hemophilia: 1999 update. Haematologica 2000; 85(Suppl. 10): 45-7.
15. Valentino LA, Ewenstein B, Navickis RJ, Wilkes MM. Central venous access devices in haemophilia. Haemophilia 2004; 10: 134-46.
16. Ewenstein BM, Valentino LA, Journeycake JM et al. Consensus recommendations for use of central venous access devices in haemophilia. Haemophilia 2004; 10: 629-48.
17. Ljung R. The risk associated with indwelling catheters in children with haemophilia. Br J Haematol 2007; 138: 580-6.
18. Komvilaisak P, Connolly B, Naqvi A, Blanchette V. Overview of the use of implantable venous access devices in the management of children with inherited bleeding disorders. Haemophilia 2006; 12(Suppl. 6): 87-93.
19. Hay CRM, DiMichele DM. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012; 119: 1335-44.
20. McCarthy WJ, Valentino LA, Bonilla AS et al. Arteriovenous fistula for long-term venous access for boys with hemophilia. J Vasc Surg 2007; 45: 986-96.
21. Mancuso ME, Berardinelli L, Beretta C, Raiteri M, Pozzoli E, Santagostino E. Improved treatment feasibility in children with hemophilia using arteriovenous fistulae: the results after seven years of follow up. Haematologica 2009; 94: 687-92.
22. Kumar R, Pruthi RK, Rodriguez V. Central Venous Access Devices (CVAD) for pediatric patients with hemophilia: a review. J Coagul Disorders 2009; 1: 85-91.
23. Ljung R, van den Berg M, Petrini P et al. Port-A-Cath usage in children with haemophilia: experience of 53 cases. Acta Paediatr 1998; 87: 1051-4.
24. McMahon C, Smith J, Khair K, Liesner R, Hann IM, Smith OP. Central venous access devices in children with congenital coagulation disorders: complications and long-term outcome. Br J Haematol 2000; 110: 461-8.
25. Collins PN, Khair KS, Liesner R, Hans IM. Complications experienced with central venous catheters in children with congenital bleeding disorders. Br J Haematol 1997; 99: 206-8.
26. Perkins JL, Johnson VA, Osip JM et al. The use of implantable venous access devices (IVADs) in children with hemophilia. J Pediatr Hematol Oncol 1997; 19: 339-44.
27. Hacker MR, Page JH, Shapiro AD, Rich-Edwards JW, Manco-Johnson MJ. Central venous access device infections in children with hemophilia: a comparison of prophylaxis and episodic therapy. J Pediatr Hematol Oncol 2007; 29: 458-64.
28. Ljung R. Central venous catheters in children with haemophilia. Blood Rev 2004; 18: 93-100.
29. Mancuso ME, Mannucci PM, Sartori A, Agliardi A, Santagostino E. Feasibility of prophylaxis and immune tolerance induction regimens in haemophilic children using fully implantable central venous catheters. Br J Haematol 2008; 141: 689-95.
30. Carcao MD. Side effects and venous access issues with immunetolerance therapy. Haemophilia 2009; 15: 494-500.
31. Ranta S, Kalajoki-Hemlmio T, Pouttu J, Makipernaa A. MRI after removal of central venous access device reveals a high number of asymptomatic thromboses in children with haemophilia. Haemophilia 2012; 18: 521-6.
32. Journeycake JM, Quinn CT, Miller KL, Zajac JL, Buchanan GR. Catheter related deep vein thrombosis in children with hemophilia. Blood 2001; 98: 1727-31.